Literature DB >> 23466619

Venous thromboembolism prophylaxis and clinical consequences in medically ill patients.

Onur Baser1, Xianchen Liu, Hemant Phatak, Li Wang, Jack Mardekian, Hugh Kawabata, Danielle Petersel, Melissa Hamilton, Eduardo Ramacciotti.   

Abstract

The objective of this study was to examine venous thromboembolism (VTE) prophylaxis use, risk reduction, and readmission in medically ill patients during hospitalization and after discharge. This 5-year retrospective study linked outpatient files from MarketScan Commercial and Medicare Supplemental databases. Patients were categorized into prophylaxis and non-prophylaxis groups based on guideline-recommended anticoagulant use from the index date to 180 days posthospital discharge and before the first VTE event date. Outcome variables were VTE events and rehospitalization. Risk adjustment was conducted within the prophylaxis group and between the prophylaxis and non-prophylaxis groups using propensity score matching. Among 4467 patients, 28.99% of the patients (n = 1295) were admitted with cancer, 18.03% (n = 805) with pneumonia, 14.06% (n = 628) with heart failure, 11.06% (n = 494) with stroke, 11.11% (n = 496) with sepsis, 8.08% (n = 361) with infectious diseases, 5.6% (n = 250) with severe respiratory disorders, 1.81% (n = 81) with inflammatory bowel disease, 1.05% (n = 47) with obesity, 0.20% (n = 9) with neurologic disorders, and 0.02% (n = 1) with acute rheumatic fever. Among those with 180-day continuous enrollment after the index date (n = 3511), 51.81% (n = 1819) received anticoagulant therapy only, 2.48% (n = 87) received mechanical compression treatment only (stocking or pneumatic compression), and 4.41% (n = 155) received both during hospitalization. Anticoagulant therapy rates ranged from 88.64% (obesity) to 32.39% (inflammatory bowel disease). Among anticoagulant therapy patients, 740 patients (40.68%) received low-molecular weight heparin only and 806 patients (44.31%) received unfractionated heparin. After risk adjustment, compared with patients without VTE prophylaxis, anticoagulant prophylaxis patients had lower VTE (3.62% vs. 4.27%, P < 0.04) and readmission rates (24.22% vs. 27.95%, P < 0.02) during the 6 months post-index hospital admission. In conclusion anticoagulant prophylaxis is underutilized and is associated with reduced VTE risk and a decrease in rehospitalizations for medically ill patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23466619     DOI: 10.1097/MJT.0b013e31826910dd

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  6 in total

Review 1.  Nutrition reconciliation and nutrition prophylaxis: toward total health.

Authors:  Phillip Tuso; Sam Beattie
Journal:  Perm J       Date:  2015

Review 2.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

3.  Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors.

Authors:  Elizabeth A Scoville; Gauree G Konijeti; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

4.  The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients.

Authors:  Shoutian Lv; Yongmei Liu; Gang Wei; Xueyan Shi; Shaoping Chen; Xuehui Zhang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.889

Review 5.  Magnitudes of Risk Factors of Venous Thromboembolism and Quality of Anticoagulant Therapy in Ethiopia: A Systematic Review.

Authors:  Bekalu Kebede; Tirsit Ketsela
Journal:  Vasc Health Risk Manag       Date:  2022-04-11

6.  Evaluation of the Padua Prediction Score ability to predict venous thromboembolism in Israeli non-surgical hospitalized patients using electronic medical records.

Authors:  O Lavon; T Tamir
Journal:  Sci Rep       Date:  2022-04-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.